AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$NOVT

Glastra Matthijs sold $69K of NOVT

Glastra Matthijs (Chief Executive Officer) sold 400 shares of NOVANTA INC (NOVT) at $171.28 on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glastra Matthijs
Published Jun 4, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NOVT
Neutral
medium confidence
Mentioned
$NOVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NOVTNeutralLow
01

Why it matters

Insider sales can influence short-term sentiment, but the presence of a 10b5-1 plan generally lowers the likelihood of a fundamental interpretation.

02

Market read

A disclosed insider sale at a specific price provides limited incremental information; any trading impact is likely sentiment-driven and short-lived.

03

What to watch

Traders may over-weight small insider sales; the more informative signals would be repeated pattern changes, larger transactions, or sales not covered by 10b5-1.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 4 for a June 2 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure (CEO/director selling shares) for Novanta, filed June 4 and dated June 2.

Company-level read

Ticker impact

$NOVTNeutralMedium confidence
Context

Novanta CEO Glastra Matthijs sold $68,512 of NOVT shares in an open-market transaction disclosed via SEC Form 4 on June 2 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment/positioning rather than a new catalyst.

Evidence & confidence

The filing provides a specific sale size and price, but no new operational, financial, or regulatory information; 10b5-1 typically reduces interpretive signal.

Market effects

Sector

Minimal—single-company insider transaction without sector-wide news.

Regional

Minimal—no geographic or macro linkage beyond the issuer.

Global

Minimal—no cross-border deal/regulatory development mentioned.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Novanta Inc

    Subject of the SEC Form 4 insider sale disclosure.

  • insider
    Glastra Matthijs

    Novanta CEO/director who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NOVT insider trading history →

Related articles

SEP 2
$AEISMed

Electronic Components Stocks Q2 Results: Benchmarking Advanced Energy (NASDAQ:AEIS)

Eight electronic components stocks reported Q2 revenues 3.3% above estimates, with next quarter's guidance 6.9% higher. Despite strong results, shares fell 7.2% on average. Advanced Energy (AEIS) saw $574.1M revenue (up 30% YoY, 5.6% beat), but its stock dropped 10%. Allient (ALNT) and Littelfuse (LFUS) also beat estimates, while nLIGHT (LASR) missed EBITDA guidance, falling 46.4%.

tradingview.com3 min
AUG 13
$NOVTMedAI 9/10

Novanta (NOVT) Q2 2026 Earnings Call Transcript

Novanta Inc. (NOVT) reported Q2 2026 revenue of $265.8 million, up 10.3% (9.3% organic). Adjusted EPS was $0.89, up 17.1%, with adjusted EBITDA of $60.7 million. The company raised 2026 guidance for revenue ($1.13B-$1.14B) and adjusted EBITDA ($273M-$278M) after completing the Riverpoint Medical acquisition, expected to add ~$65M revenue and ~$25M adjusted EBITDA in 2H26.

fool.com6 min
AUG 5
$NOVTHighAI 9/10

Novanta Announces Financial Results for the Second Quarter 2026

Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.

leaderpost.com6 min
AUG 5
$NOVTHigh

NOVANTA INC (NOVT): Results of Operations and Financial Condition

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and Adjusted EBITDA increased 16% to $61 milli

SEC EDGAR 8-K6 min
JUL 27
$NOVTMedAI 8/10

Novanta Completes Acquisition of Riverpoint Medical

Novanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.

leaderpost.com5 min